Inside Drug Pricing

Maryland PDAB To Use MFP If Board Moves Forward With UPL

By Luke Zarzecki / November 19, 2025 at 6:48 PM

The Maryland Prescription Drug Affordability Board (PDAB) will use CMS’ negotiated maximum fair prices (MFP) as upper payment limits for Boehringer Ingelheim’s Jardiance and AstraZeneca’s Farxiga if the board elects to move forward with limiting sale prices in the state, drawing ire from the companies.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.

FEATURES

NEWSLETTERS

ABOUT US

Inside Health Policy is a subscription-fee-based daily digital news service from Inside Washington Publishers.

SITE LICENSES

Economical site license packages are available to fit any size organization, from a few people at one location to company-wide access. For more information on how you can get greater access to Inside Health Policy for your office, contact Online Customer Service at 703-416-8505 or healthpolicy@iwpnews.com.

STAY CONNECTED

Inside Drug Pricing

Maryland PDAB To Use MFP If Board Moves Forward With UPL

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.